PMS29 CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
Abstract
Authors
D Zou O Desjardins N Tsao R Goeree